These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34797442)

  • 1. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy.
    Picetti D; Kim J; Zhu W; Sandborn WJ; Jairath V; Singh S
    Dig Dis Sci; 2022 Jul; 67(7):3115-3123. PubMed ID: 34797442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy.
    Singh S; Kim J; Zhu W; Dulai PS; Sandborn WJ; Jairath V
    Aliment Pharmacol Ther; 2020 Aug; 52(3):481-491. PubMed ID: 32573825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study.
    Seo J; Kim S; Hong SW; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Kim YJ; Ye BD
    Aliment Pharmacol Ther; 2024 Aug; 60(3):389-400. PubMed ID: 38866064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.
    Ungaro RC; Limketkai BN; Jensen CB; Allin KH; Agrawal M; Ullman T; Colombel JF; Jess T
    Gut; 2019 Jun; 68(6):977-984. PubMed ID: 30420398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes.
    Ungaro RC; Limketkai BN; Jensen CB; Yzet C; Allin KH; Agrawal M; Ullman T; Burisch J; Jess T; Colombel JF
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1152-1160.e1. PubMed ID: 31419574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.
    Gjuladin-Hellon T; Gordon M; Iheozor-Ejiofor Z; Akobeng AK
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD008414. PubMed ID: 31220875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy.
    Castillo-Regalado E; Ríos R; Aràjol C; Gely C; Márquez L; Calafat M; González-Muñoza C; Cañete F; Mesonero F; Guardiola J; Garcia-Planella E; Mañosa M; Domènech E
    Gastroenterol Hepatol; 2023 Mar; 46(3):164-170. PubMed ID: 36179946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Wang Y; MacDonald JK; Hanauer S
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease.
    Schoepfer AM; Bortolotti M; Pittet V; Mottet C; Gonvers JJ; Reich O; Fournier N; Vader JP; Burnand B; Michetti P; Froehlich F
    Aliment Pharmacol Ther; 2014 Oct; 40(8):930-7. PubMed ID: 25146487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-aminosalicylic acid dependency in Crohn's disease: a Danish Crohn Colitis Database study.
    Duricova D; Pedersen N; Elkjaer M; Jensen JK; Munkholm P
    J Crohns Colitis; 2010 Nov; 4(5):575-81. PubMed ID: 21122562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
    Gordon M; Taylor K; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.
    Gordon M; Naidoo K; Thomas AG; Akobeng AK
    Cochrane Database Syst Rev; 2011 Jan; (1):CD008414. PubMed ID: 21249709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural History of Pediatric Patients With Crohn's Disease Treated With Mesalamine Therapy.
    Young DD; Perry S; Malay S; Sferra TJ; Finkler M; Moses J
    JPGN Rep; 2023 Nov; 4(4):e379. PubMed ID: 38034435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.
    Rubin DT; Mody R; Davis KL; Wang CC
    Aliment Pharmacol Ther; 2014 May; 39(10):1143-55. PubMed ID: 24697826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease-A nationwide cohort study.
    Atia O; Goren I; Fischler TS; Weisband YL; Greenfeld S; Kariv R; Ledderman N; Matz E; Rimon RM; Dotan I; Turner D; Yanai H
    Aliment Pharmacol Ther; 2023 May; 57(9):1004-1013. PubMed ID: 36894866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis.
    Ford AC; Khan KJ; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Mar; 106(3):413-20. PubMed ID: 20717106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.
    Ford AC; Kane SV; Khan KJ; Achkar JP; Talley NJ; Marshall JK; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):617-29. PubMed ID: 21407190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
    Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA
    Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.
    Stocco G; Cuzzoni E; De Iudicibus S; Favretto D; Malusà N; Martelossi S; Pozzi E; Lionetti P; Ventura A; Decorti G
    World J Gastroenterol; 2015 Mar; 21(12):3571-8. PubMed ID: 25834322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.